LUXONOMY CONFIDENTIAL™ — The longevity luxury economy: from selling wellness to selling healthier years
by LUXONOMY
Press play to listen to this article
VOXREAD™ by LUXONOMY™ Group
Ready to listen
0:00
0:00
Your browser does not support speech synthesis. You can continue reading the article normally.
LUXONOMY CONFIDENTIAL™ · Expanded edition · 5 November 2026. Strategic intelligence for boards, investors, hotels, clinics and property developers.
Longevity may reorganise luxury around health, autonomy and continuity. Distinguish exceptional experiences, healthcare delivery and promises of additional healthy years: their evidence, costs and responsibilities differ.
This dossier examines five operators and primary economic and scientific sources, with contribution, renewal and capacity models, a diligence rubric, defined indicators and a 90-day plan. Original scenarios are assumptions, and commercial claims remain distinct from clinical evidence.
Report contents
- 1. Executive summary: continuity is the opportunity
- 2. What can be measured and what remains a promise
- 3. Market scale and the crucial GWI revision
- 4. Five business models and their value pools
- 5. Five operators: public offers and diligence questions
- 6. Customer segmentation and commercial validation
- 7. Clinical evidence: establish the core before the frontier
- 8. Advanced diagnostics: finding more creates obligations
- 9. Therapeutic innovation and explicit responsibility
- 10. Unit economics: EUR 25,000 revenue is not EUR 25,000 value
- 11. Renewal, clinical capacity and cash obligations
- 12. Local sizing: accessible demand and serviceable capacity
- 13. Hospitality and healthcare: a clear operating split
- 14. Spain and the EU: authorisation and advertising
- 15. Health data and AI: personalisation with boundaries
- 16. Health-oriented residences: operations after the sale
- 17. Longevity Integrity Score™: documentary diligence, not certification
- 18. Board indicators: usefulness, harm and contribution
- 19. The 90-day implementation dossier
- 20. Stress scenarios and prepared responses
- 21. Investment diligence: twenty documentary questions
- 22. The board mandate: approve, condition or reject
- 23. Method, scope and limitations
- 24. Primary sources and evidence register
Additional working chapters
- 25. Annual product blueprint
- 26. Pricing architecture
- 27. Three-year cohort model
- 28. Partner procurement
- 29. Workforce and capacity
- 30. Outcome evidence pack
- 31. Investment decision cases
- 32. Twelve-month learning agenda
PREMIUM CONTENT
Continue reading with Premium access.
Discover more from LUXONOMY
Subscribe to get the latest posts sent to your email.
Tags







